News
Why Omeros Corporation Is the Best Buy in Biotech Right Now
Omeros Corporation (NASDAQ: OMER) stock soared after the company reported surprisingly good results recently, but there's a lot more fuel in the tank to propel it even higher. This small-cap....
This Small-Cap Biotech Stock Is Onto Something Big
I recently had the pleasure of chatting with Flexion Therapeutics (NASDAQ: FLXN) CEO Mike Clayman about the company's plans for Zilretta, a newly approved medicine treating osteoarthritis of the....
Why Collegium Pharmaceutical Shares Are Tumbling 12.9% Today
After FDA commissioner Scott Gottlieb issued a statement suggesting an easier path to winning approval for generic opioids that are abuse deterrent, shares in Collegium Pharmaceutical's (NASDAQ:....
3 Reasons Novavax Stock Could Double in 2018
Charles Dickens' introduction to A Tale of Two Cities sort of applies to Novavax's (NASDAQ: NVAX) experience in 2017 so far: "It was the best of times, it was the worst of times..."At two....
Why Vascular Biogenics Ltd. Is Tanking Today
After the company released the pricing details of its just-announced common stock offering, shares of Vascular Biogenics (NASDAQ: VBLT), a clinical-stage biotech focused on cancer, fell 18% as of....
Medigene: Unter 10 EUR? Ist doch super!
Die Anteile des Biotechnologieunternehmens Medigene zeigen in diesem Jahr riesige Kursausschläge. Von 30 bis 70 Prozent nach oben und von 30 bis 45 Prozent nach unten ist fast alles dabei. Allein....
Can This Tiny Biotech Stock Pay Off Big for Celgene?
Celgene Corp (NASDAQ: CELG) loves cozying up to emerging biotech stocks working on next-generation medicine, and one of those collaborations is with Jounce Therapeutics (NASDAQ: JNCE). Celgene....
Here's Why Achillion Pharmaceuticals Is Soaring 19.5% Today
After Achillion Pharmaceuticals (NASDAQ: ACHN) priced its shares that Johnson & Johnson (NYSE: JNJ) is selling at $2.75 each, the company is rallying back 19.5% as of 3:15 p.m. EST.Johnson....
Where Will Aurinia Pharmaceuticals Be in 5 Years?
Predicting the future isn't hard at all. Predicting the future accurately is a different matter altogether.I wanted to state that at the outset before attempting to predict how things will unfold....
Here's Why Sangamo Therapeutics Rose as Much as 16.3% Today
Shares of Sangamo Therapeutics (NASDAQ: SGMO) rose over 16% today after the company announced that the first patient had been dosed in a phase 1/2 trial evaluating the potential for its....
Here's Why Acorda Therapeutics Got Crushed Today
Shares of biopharma Acorda Therapeutics (NASDAQ: ACOR) dropped as much as 40.1% Wednesday after the company issued an update on its second-leading drug candidate. The company is increasing the....
Why Achillion Pharmaceuticals Stock Is Falling Today
Shares of Achillion Pharmaceuticals (NASDAQ: ACHN) are falling hard today after the company announced that Johnson & Johnson (NYSE: JNJ) has decided to sell 18.4 million of the drugmaker's....
Here's What You Need to Know About Intrexon's Third-Quarter 2017 Earnings
Shares of synthetic biology conglomerate Intrexon (NYSE: XON) were crushed following the release of third-quarter 2017 earnings last week. Although missing Wall Street's revenue expectations....
Quantum Genomics announces recruitment of first patients in the NEW-HOPE arterial hypertension study in the United States
Press Release
Paris & New York, 15 November 2017
· A study to improve targeting is being carried out in the United States
· NEW-HOPE: Galien MedStartUp Award-Winning Phase II Clinical....
QUANTUM GENOMICS : Recrutement aux Etats-Unis des premiers patients de l'étude NEW-HOPE dans l'hypertension artérielle
Communiqué de presse
Paris, le 15 novembre 2017
Une étude menée aux Etats-Unis pour un meilleur ciblage
NEW-HOPE : un essai clinique de phase II récompensé par le prix Galien....
Keryx Biopharma Down 17% Despite Drug Approval
Last week, Keryx Biopharmaceuticals (NASDAQ: KERX) fell a whopping 17% after missing analyst estimates for its key drug, Auryxia, which is used to control phosphorus levels in patients with....
Jounce Therapeutics, Inc. (JNCE) Q3 2017 Earnings Conference Call Transcript
Image source: The Motley Fool.Jounce Therapeutics, Inc. (NASDAQ: JNCE) Q3 2017 Earnings Conference CallNov. 13, 2017 8:00 a.m. ETOperatorContinue readingSource: Fool.com
It's Not Too Late to Buy Dynavax Stock After Its Hepatitis B Vaccine Approval
Some thought this day would never arrive. After two prior failed attempts, Dynavax Technologies (NASDAQ: DVAX) finally won approval for hepatitis B vaccine Heplisav-B. The company announced the....
Puma Biotechnology Is Down 19% -- Is Its Stock a Bargain?
Despite a fairly strong third-quarter earnings release that hit the wires after the bell Thursday, mid-cap biotech Puma Biotechnology's (NASDAQ: PBYI) shares got pummeled today. Specifically,....
Why Intrexon Corporation Stock Got Crushed Today
Shares of the synthetic-biology company Intrexon Corporation (NYSE: XON) lost over a quarter of their value today -- down 25.63% -- on nearly nine times the average daily volume. The culprit? An....
Momenta Pharmaceuticals, Inc.'s Rough Month
Momenta Pharmaceuticals (NASDAQ: MNTA) has had a rough month or so after seeing Mylan (NASDAQ: MYL) pass it up to get the first approval of a generic version of Teva Pharmaceutical's (NYSE: TEVA)....
This Is Why Omeros Corporation Shares Are Rocketing 33% Higher Today
Despite already rewarding investors with more than a 100% return this year, shares of Omeros Corporation (NASDAQ: OMER) are charging 33.3% higher at 1:45 p.m. EST Friday following the release of....
BOIRON : Formulaire de déclaration mensuelle des droits de vote au 31 octobre 2017
Le 10 novembre 2017
Publication
du nombre d'actions composant le capital et du nombre total de droits de vote
(articles L. 233-8 II du code de commerce et 223-16 du règlement général de....
ImmunoGen, Inc. Moves Forward
Like most biotechs without a drug generating revenue, ImmunoGen's (NASDAQ: IMGN) third-quarter earnings were a review of what it's accomplished and a look at what investors can expect in the....
Why Inovio Pharmaceuticals Inc. Is Sinking Today
In response to the company reporting disappointing third-quarter results, shares of Inovio Pharmaceuticals (NASDAQ: INO), a clinical-stage biotech focused on vaccines, fell 14% as of 2:15 p.m. EST....